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 2 
ABSTRACT 1 
Protein aggregates are associated with a variety of debilitating human 2 
diseases, but they can have functional roles as well. Both pathological and 3 
non-pathological protein aggregates display tremendous diversity, with 4 
substantial differences in aggregate size, morphology and structure. 5 
Among the different aggregation types, amyloids are particularly 6 
remarkable, because of their high degree of order and their ability to form 7 
self-perpetuating conformational states. Amyloids form the structural basis 8 
for a group of proteins called prions, which have the ability to generate new 9 
phenotypes by a simple switch in protein conformation that does not 10 
involve changes in the sequence of the DNA. Although protein aggregates 11 
are notoriously difficult to study, recent technological developments and, 12 
in particular, the use of yeast prions as model systems, have been very 13 
instrumental in understanding fundamental aspects of aggregation. Here, 14 
we provide a range of biochemical and yeast genetic methods that are 15 
currently used in our laboratory to study protein aggregation and the 16 
formation of amyloids and prions. 17 
18 
 3 
1. Introduction 1 
More than 40 years ago an unusual nonsense suppressor phenotype was 2 
reported that was inherited in a non-Mendelian manner (Cox 1965). This 3 
phenotype, [PSI+], was later found to be caused by a change in the conformation 4 
of the translation termination factor Sup35p (Patino et al. 1996; Paushkin et al. 5 
1996). Shortly after the discovery of [PSI+], a different genetic element, [URE3], 6 
was isolated (Lacroute 1971) and the causal agent was afterwards indentified as 7 
a conformationally altered form of the nitrogen catabolite repressor Ure2p 8 
(Wickner 1994). Ure2p and Sup35p are the founding members of an intriguing 9 
class of yeast proteins that can act as protein-based epigenetic elements. Also 10 
known as prions, these proteins can interconvert between at least two structurally 11 
and functionally distinct states, at least one of which adopts a self-propagating 12 
aggregated state. A switch to the aggregated prion state generates new 13 
phenotypic traits, which increase the phenotypic heterogeneity of yeast 14 
populations (Shorter and Lindquist 2005; Alberti et al. 2009)..   15 
 Sup35 is a translation termination factor. When Sup35p switches into a 16 
prion state, a large fraction of the cellular Sup35p is sequestered into insoluble 17 
aggregates. The resulting reduction in translation termination activity causes an 18 
increase in ribosomal frame-shifting (Namy et al. 2008; Park et al. 2009) and stop 19 
codon read-through (Liebman and Sherman 1979; Patino et al. 1996; Paushkin 20 
et al. 1996). The sequences downstream of stop codons are highly variable, and 21 
this, in turn, facilitates the sudden generation of new phenotypes by the 22 
uncovering of previously hidden genetic variation (Eaglestone et al. 1999; True 23 
 4 
and Lindquist 2000; True et al. 2004). The other well-understood prion protein, 1 
Ure2p, regulates nitrogen catabolism through its interaction with the 2 
transcriptional activator Gln3p. Its prion state, [URE3], causes the constitutive 3 
activation of Gln3p and consequently gives cells the ability to utilize poor nitrogen 4 
sources in the presence of a rich nitrogen source (Aigle and Lacroute 1975; 5 
Wickner 1994).  6 
 The epigenetic properties of Sup35p and Ure2p reside in structurally 7 
independent prion-forming domains (PrDs) with a strong compositional bias for 8 
residues such as glutamine and asparagine (Edskes et al. 1999; Li and Lindquist 9 
2000; Santoso et al. 2000; Sondheimer and Lindquist 2000). This observation 10 
stimulated the first sequence-based query for additional yeast prions 11 
(Sondheimer and Lindquist 2000) that ultimately lead to the identification of an 12 
additional prion protein called Rnq1. The prion form of Rnq1, [RNQ+], was found 13 
to underlie the previously characterized non-Mendelian trait [PIN+], which 14 
facilitates the de novo appearance of [URE3] and [PSI+] (Derkatch et al. 2000; 15 
Derkatch et al. 2001). Rnq1, however, not only induces benign conformational 16 
transitions of other prion proteins, it can also induce toxic conformational 17 
changes of glutamine-expansion (polyQ) proteins that cause Huntington's 18 
disease and several other late-onset neurodegenerative disorders. When polyQ 19 
fragments are expressed in yeast, they create a polyQ length-dependent toxicity 20 
that is accompanied by the formation of visible amyloid-containing aggregates in 21 
a [RNQ+]-dependent manner (Krobitsch and Lindquist 2000; Duennwald et al. 22 
2006a). Yeast prions have been widely used as model systems for the study of 23 
 5 
protein aggregation in vivo. They were tremendously useful for unraveling 1 
several aspects of protein aggregation, including the formation of structural 2 
variants, known as prion strains, or the presence of transmission barriers 3 
between related prion proteins (Tessier and Lindquist 2009). 4 
Protein aggregation is a highly complex process that is determined by 5 
intrinsic factors, such as the sequence and structure of the aggregation-prone 6 
protein, as well as extrinsic factors, such as temperature, salt concentration and 7 
chaperones (Chiti and Dobson 2006; Rousseau et al. 2006). A particular type of 8 
aggregation underlies the self-perpetuating properties of prions. The 9 
biochemically well-characterized prions have an amyloid conformation. Amyloid 10 
is a highly ordered fibrillar aggregate. The fibril core is a continuous sheet of β- 11 
strands that are arranged perpendicularly to the fibril axis. The exposed β- 12 
strands at the ends of the fibril allow amyloids to polymerize by the continuous 13 
incorporation of polypeptides of the same primary sequence. This extraordinary 14 
self-templating ability allows prions to generate and multiply a transmissible 15 
conformational state (Ross et al. 2005; Shorter and Lindquist 2005; Caughey et 16 
al. 2009). Prions can spontaneously switch to this transmissible state from a 17 
default conformational state that is usually soluble. 18 
In a recent systematic attempt to discover new prions in yeast we used the 19 
unusual amino acid biases of known PrDs to predict novel prionogenic proteins in 20 
the S. cerevisiae proteome. We subjected one hundred such prion candidates to 21 
a range of genetic, cell biological and biochemical assays to analyze their prion- 22 
and amyloid-forming propensities, and determined that at least twenty-four yeast 23 
 6 
proteins contain a prion-forming domain (Alberti et al. 2009). Our findings 1 
indicate that prions play a much broader role in yeast biology and support 2 
previous assumptions that prions buffer yeast populations against environmental 3 
changes. The fact that prions are abundant in yeast suggests that prions also 4 
exist in other organisms. Moreover, many more examples of functional 5 
aggregation, which do not involve an epigenetic mechanism for the inheritance of 6 
new traits, are likely to be discovered. The methods and techniques described 7 
here have vastly increased our understanding of protein aggregation in yeast. 8 
They will allow us to identify additional aggregation-prone proteins in yeast and 9 
other organisms and will advance our understanding of the pathological and non- 10 
pathological functions of aggregates. 11 
 12 
2. Methods 13 
2.1. Detecting protein aggregation in yeast cells 14 
Protein aggregates are formed when large numbers of polypeptides cooperate to 15 
form non-native molecular assemblies. These structures are highly diverse, with 16 
differences in the amount of β-sheet content, their overall supramolecular 17 
organization and their ability to induce the co-aggregation of other proteins (Chiti 18 
and Dobson 2006; Rousseau et al. 2006). Notwithstanding the multifactorial 19 
nature and complexity of protein aggregation, protein aggregates can 20 
simplistically be classified as disordered (amorphous) or ordered (amyloid-like). 21 
Amorphous aggregates are generally not well characterized due to their 22 
tremendous structural plasticity. Recent studies, however, indicate that the 23 
 7 
constituent proteins of some amorphous aggregates have a conformation that is 1 
similar to their native structure in solution (Qin et al. 2007; Vetri et al. 2007). 2 
Ordered aggregates, on the other hand, contain greater amounts of β-sheet 3 
content and form densely packed amyloid fibers. Amyloid-like aggregates can be 4 
distinguished from disordered aggregates based on their resistance to physical 5 
and chemical perturbations that affect protein structure, such as increased 6 
temperature, ionic detergents or chaotropes. In the following section we provide 7 
a variety of methods for the analysis of diverse protein aggregates in yeast cells. 8 
 9 
2.1.1. Fluorescence microscopy and staining of amyloid-like aggregates 10 
Aggregating proteins coalesce into macroscopic assemblies that can be 11 
visualized by fluorescence microscopy. This very convenient method for following 12 
aggregation in cells has greatly expanded our understanding of protein 13 
misfolding diseases  and other non-pathological aggregation-based phenomena 14 
such as prions (Johnston et al. 1998; Garcia-Mata et al. 1999; Kaganovich et al. 15 
2008). Two different experimental approaches are available for the direct 16 
visualization of protein aggregates in cells: (1) The aggregate-containing cells 17 
can be fixed and treated with an antibody specific to the aggregation-prone 18 
protein, or (2) the aggregation-prone protein can be expressed as a chimera with 19 
a fluorescent protein (FP). Either approach has both advantages and 20 
disadvantages. Immunofluorescence microscopy requires an extensive 21 
characterization of the antibody to determine its specificity and to ensure that it is 22 
able to recognize the aggregated state of the protein. The benefit, however, is 23 
 8 
that the aggregation-prone protein can be expressed unaltered. In fact, tagging of 1 
an aggregation-prone protein with an FP can severely interfere with its 2 
aggregation propensity by changing its overall solubility. The FP tag could also 3 
sterically interfere with the formation of the amyloid structure. Moreover, some 4 
FPs are known to self-interact. Particularly problematic in this regard are older 5 
versions of DsRed, although we have observed that in rare cases GFP fusions 6 
can also cause spurious aggregation. Generally, GFP-driven aggregation does 7 
not react with thioflavin T (discussed below) and forms a characteristic well- 8 
defined high molecular weight species when analyzed by SDD-AGE (described 9 
in section 2.1.3). Experiments with FP chimeras therefore require some caution 10 
in the interpretation of the results and we recommend performing additional 11 
assays to independently establish whether a protein is aggregation-prone or not.  12 
 Despite these drawbacks, using FP-chimeras to study protein aggregation 13 
has several advantages, particularly cost effectiveness, ease of use and rapid 14 
generation of results. Diverse yeast expression vectors are now available for the 15 
tagging of aggregation-prone proteins with FPs, most of which are suitable for 16 
determining the aggregation propensities of a protein (Krobitsch and Lindquist 17 
2000; Duennwald et al. 2006a; Alberti et al. 2007; Alberti et al. 2009). The choice 18 
of the promoter and the copy number of the yeast plasmid are also important 19 
parameters that need to be considered carefully. Expression from high copy two- 20 
micron plasmids is highly variable, thus allowing the sampling of a range of 21 
different protein concentrations. This property is desirable if the goal is to 22 
determine whether a protein is generally able to nucleate and enter an amyloid- 23 
 9 
like state in a cellular environment. Low-copy CEN-based plasmids and 1 
expression cassettes for integration into the genome, however, have more 2 
steady expression levels, a property which can be useful if more consistent 3 
aggregation behavior is desired. We usually try to avoid constitutive promoters, 4 
as aggregation can be associated with toxicity and frequently triggers growth 5 
arrest or cell death. Inducible promoters like GAL1 are more suitable and 6 
transient expression for 6-24 hours is usually sufficient to induce aggregation in a 7 
significant fraction of the cell population.  8 
 Aggregation-prone proteins form foci that can be visualized by 9 
fluorescence microscopy. Yeast cells expressing aggregation-prone proteins 10 
form two characteristic types of fluorescent foci (Figure 1A): (1) ring-like 11 
structures that localize to the vacuole and/or just below the plasma membrane, or 12 
(2) punctate structures that can be distributed all over the cytoplasm but 13 
preferentially reside close to the vacuole (Derkatch et al. 2001; Zhou et al. 2001; 14 
Ganusova et al. 2006; Taneja et al. 2007; Alberti et al. 2009). The fibrillar 15 
appearance of ring-like structures and their reactivity with amyloid-specific dyes 16 
suggests that they consist of laterally associated amyloid fibers. Punctate foci, on 17 
the other hand, do not always stain with amyloid-binding dyes, suggesting that 18 
these structures can also be of the non-amyloid or amorphous type (Douglas et 19 
al. 2008). The two types of aggregation can be distinguished based on their 20 
fluorescence intensity and their pattern of aggregation. Rings and large punctate 21 
foci with very bright fluorescence are indicative of highly ordered amyloid fibers, 22 
 10 
whereas multiple small puncta with low brightness usually do not react with 1 
amyloid-specific dyes and are therefore of the amorphous type. 2 
 To conclusively determine whether these foci result from amorphous or 3 
amyloid-like aggregation, we use a staining protocol with the amyloid-specific dye 4 
Thioflavin T (ThT). ThT has an emission spectrum that is red-shifted upon 5 
amyloid-binding, therefore allowing co-localization with aggregation-prone 6 
proteins that are tagged with yellow fluorescent protein. However, staining yeast 7 
cells with ThT can lead to high background levels and thus we recommend 8 
performing ThT co-staining experiments only for proteins with relatively high 9 
expression levels. To grow the yeast cells for staining with ThT, a culture is 10 
inoculated in the appropriate selective medium for overnight growth, followed by 11 
dilution and regrowth until it reaches an OD600 of 0.25 - 1.0. Then 8 ml of the 12 
culture are transferred onto a 150 ml Nalgene bottle-top filter (45 mm diameter, 13 
0.2 µM pores, SFCA membrane) and the solution is filtered by applying a 14 
vacuum. When the solution has passed through the filter, the vacuum is halted 15 
and 5 ml of freshly prepared fixing solution (50 mM H2KPO4, pH 6.5; 1 mM 16 
MgCl2; 4% formaldehyde) is added to the cells on the filter. The cells are 17 
resuspended by swirling and the suspension is then transferred to a 15 ml tube. 18 
The cells are incubated at room temperature for 2 hrs and vortexed briefly every 19 
30 min.  20 
 The fixed cells are collected by a brief centrifugation step (2 min at 2,000 21 
rcf) and the supernatant is removed carefully and completely. The cells are then 22 
resuspended in 5 ml buffer PM prepared freshly (0.1 M H2KPO4, pH 7.5; 1 mM 23 
 11 
MgCl2) and collected again by centrifugation. After the supernatant is removed 1 
completely the cells are resuspended in buffer PMST (0.1 M H2KPO4, pH 7.5; 1 2 
mM MgCl2; 1 M Sorbitol; 0.1% Tween 20; containing 1 x EDTA protease inhibitor 3 
mix from Roche). The volume of the PMST buffer should be adjusted to generate 4 
a final cell density of 10 OD600. 100 µl of the cell suspension is then transferred 5 
to a 0.5-ml Eppendorf tube. 0.6 µl of ß-mercaptoethanol and 20 µl of 20,000 U/ml 6 
yeast lytic enzyme (ICN, or use zymolyase at 1mg/ml) are added and the 7 
spheroplasted cells are incubated on a rotating wheel at room temperature for 15 8 
min for spheroplasting. The spheroplasted cells are then resuspended gently in 9 
100 µl PMST, collected by centrifugation and the resuspension step is repeated 10 
once. Subsequently, the cells are incubated in PBS (pH 7.4) containing 0.001% 11 
ThT for 20 minutes, washed three times with PBS and then used immediately for 12 
fluorescence microscopy. 13 
 The pattern of aggregation is protein-specific, dependent on the level and 14 
duration of expression and regulated by the physiological state of the cell. Many 15 
yeast prion proteins, for instance, proceed through a maturation pathway that 16 
includes an early stage with ring-like aggregation patterns and a later stage with 17 
punctate cytoplasmic distribution (Alberti et al. 2009). Other amyloidogenic 18 
proteins such as glutamine-expanded versions of huntingtin exon 1 almost 19 
exclusively form punctate foci, when expressed at comparable levels. 20 
Interestingly, toxic and non-toxic aggregates of glutamine-expanded huntingtin 21 
have distinct subcellular aggregation patterns. Toxic huntingtin forms multiple 22 
 12 
punctuate foci, whereas the non-toxic structural variant is present in a single 1 
cytosolic focus (Duennwald et al. 2006a; Duennwald et al. 2006b). 2 
 Yeast cells have two different aggresome-like compartments to deal with 3 
aggregation-prone proteins such as huntingtin (Kaganovich et al. 2008). These 4 
compartments, called JUNQ and IPOD, contain predominantly soluble or 5 
insoluble misfolded proteins, respectively. The JUNQ is believed to provide a 6 
subcellular location for the proteasome-dependent degradation of misfolded 7 
proteins, whereas the IPOD is enriched for chaperones like Hsp104 and seems 8 
to be a place for the sequestration of insoluble protein aggregates. Targeting to 9 
either of the compartments most likely influences the localization of aggregation- 10 
prone proteins, but the mechanisms of targeting and the factors involved in the 11 
maintenance of the compartments remain to be determined.   12 
 13 
2.1.2. Sedimentation assay 14 
In addition to their reactivity with amyloid-specific dyes like ThT, other criteria can 15 
be used experimentally to determine whether intracellular aggregates are 16 
amyloid-like, such as their unusual resistance to chemical solubilization..The 17 
detergent insolubility of amyloids has been used to isolate amyloid-containing 18 
fractions from yeast cell lysate by centrifugation (Sondheimer and Lindquist 19 
2000; Bradley et al. 2002). In a typical amyloid sedimentation experiment 10 ml 20 
of yeast cells are grown to mid-logarithmic phase. The cells are collected by 21 
centrifugation and washed in water. The cell pellet is then resuspended in 300 µl 22 
of lysis buffer (50 mM Tris, pH 7.5; 150 mM NaCl, 2 mM EDTA, 5% glycerol). To 23 
 13 
inhibit proteolysis we supplement the lysis buffer with 1 mM 1 
phenylmethylsulphonyl fluoride (PMSF), 50 mM N-ethylmaleimide (NEM) and 1 x 2 
EDTA-free protease inhibitor mix (Roche). The suspension is transferred to a 3 
1.5 ml Eppendorf tube containing 300 µl of 0.5 mm glass beads. The cells are 4 
then lysed using a bead beater at 4°C and are immediately placed on ice. 300 µl 5 
of cold RIPA buffer (50 mM Tris, pH 7.0; 150 mM NaCl; 1% Triton X-100; 0.5% 6 
Deoxycholate; 0.1% SDS) is added and the lysate is vortexed for 10 seconds. 7 
Subsequently, the crude lysate is centrifuged for 2 min at 800 rcf (4°C) to pellet 8 
the cell debris. The sedimentation assay is performed by centrifuging 200 µl of 9 
the supernatant in a TLA 100-2 rotor for 30 min at 80,000 rpm and 4°C using an 10 
Optima TL Beckman ultracentrifuge. Equal volumes of unfractionated (total) and 11 
supernatant samples are incubated in sample buffer containing 2% SDS and 2% 12 
β-mercaptoethanol at 95°C for 5 min. The pellet is resuspended in 200 µl of a 1:1 13 
mixture of lysis buffer and RIPA buffer containing protease inhibitors and boiled 14 
in sample buffer under the same conditions described above. The samples are 15 
then analyzed by SDS-PAGE and immunoblotting with an antibody specific to the 16 
aggregation-prone protein. If a putative prion is analyzed, it should predominantly 17 
be detectable in the supernatant of prion-free cells and in the pellet fraction of 18 
prion-containing cells (see Figure 1B for an example). 19 
 20 
2.1.3. Semidenaturing detergent-agarose gel electrophoresis (SDD-AGE) 21 
The recent invention of semi-denaturing detergent-agarose gel electrophoresis 22 
(SDD-AGE) very conveniently allows the resolution of amyloid polymers based 23 
 14 
on size and insolubility in detergent (see Figure 1C for an example) (Bagriantsev 1 
et al. 2006). We adapted SDD-AGE for large-scale applications, allowing 2 
simultaneous detection of SDS-insoluble conformers of tagged proteins in a large 3 
number of samples (Halfmann and Lindquist 2008). This advanced version of 4 
SDD-AGE enables one to perform high-throughput screens for novel prions and 5 
other amyloidogenic proteins.  6 
 As a first step it is necessary to cast the detergent-containing agarose gel. 7 
Standard equipment for horizontal DNA electrophoresis can be used and the size 8 
of the gel casting tray and the comb should be adjusted according to the number 9 
and volume of the samples. We usually prepare a 1.5% agarose solution 10 
(medium gel-strength, low EEO) in 1 x TAE. The agarose solution is heated in a 11 
microwave until the agarose is completely dissolved. Subsequently, SDS is 12 
added to 0.1% from a 10% stock. The agarose solution is then poured into the 13 
casting tray. After the gel has set, the comb is removed and the gel is placed into 14 
the gel tank. The gel is then completely submerged in 1 x TAE containing 0.1% 15 
SDS. 16 
 The following lysis procedure is optimized for large numbers of small 17 
cultures processed in parallel, although it can be easily modified for individual 18 
cultures of larger volume. For high-throughput analysis of yeast lysates we use 2 19 
ml cultures grown overnight with rapid agitation in 96-well blocks. The cells are 20 
harvested by centrifugation at 2,000 rcf for 5 min and then resuspended in water. 21 
After an additional centrifugation step and removal of the supernatant, the cells 22 
are resuspended in 250 µl spheroplasting solution (1.2 M D-sorbitol; 0.5 mM 23 
 15 
MgCl2; 20 mM Tris, pH 7.5; 50 mM β-mercaptoethanol; 0.5 mg/ml Zymolyase 1 
100T) and incubated for 1 hr at 30°C. The spheroplasted cells are collected by 2 
centrifugation at 800 rcf for 5 min and the supernatant is removed completely. 3 
The pelleted spheroplasts are then resuspended in 60 µl lysis buffer (20 mM Tris 4 
7.5; 10 mM β-mercaptoethanol; 0.025 U/µl Benzonase; 0.5% Triton X-100; 2 x 5 
HALT protease inhibitor from Sigma-Adlrich). The 96-well block is covered with 6 
tape and vortexed at high speed for 1 min and then incubated for an additional 7 
10 min at room temperature. The cellular debris is sedimented by centrifugation 8 
at 4,000 rcf for 2 min and the supernatant is carefully transferred to a 96-well 9 
plate. As a next step, 4 x sample buffer (2 x TAE; 20% glycerol; 8% SDS; 10 
bromophenol blue to preference) is added to a final concentration of 1 x, followed 11 
by brief vortexing to mix.  12 
 In SDS-containing buffers amyloid-like aggregates are stable at room 13 
temperature, but can be disrupted by boiling. Therefore, samples are incubated 14 
for an additional 10 min at room temperature, or, as a negative control, incubated 15 
at 95°C. Most amyloids will be restored to monomers by the 95°C treatment. The 16 
samples are then loaded onto the agarose gel. We usually also load one lane 17 
with pre-stained SDS-PAGE marker, enabling us to verify proper transfer and to 18 
estimate the size of unpolymerized SDS-soluble conformers. In addition, it is 19 
important to use protein aggregation standards. [psi-] and [PSI+] cell lysates or 20 
lysates of yeast cells overexpressing the huntingtin length variants Q25 (non- 21 
amyloid) and Q103 (amyloid) can be used for this purpose. The electrophoresis 22 
is performed at low voltage (≤ 3 V/cm gel length) until the dye front reaches ~1 23 
 16 
cm from the end of the gel. It is important that the gel remains cool during the run 1 
since elevated temperatures can reduce the resolution. 2 
For the blotting procedure, we prefer a simple capillary transfer using a dry 3 
stack of paper towels for absorption. One piece of nitrocellulose and 8 pieces of 4 
GB002 blotting paper (or an equivalent substitute) are cut to the same 5 
dimensions as the gel. An additional piece of GB002, which serves as the wick, 6 
is cut to be about 20 centimeters wider than the gel. The nitrocellulose, wick, and 7 
4 pieces of GB002 are immersed in 1 x TBS (0.1 M Tris-HCl, pH 7.5; 0.15 M 8 
sodium chloride). A stack of dry folded paper towels is assembled that is about 2 9 
cm thick and the same length and width of the gel. On top of the stack of paper 10 
towels 4 pieces of dry GB002 are placed, then one piece of wet GB002, and 11 
finally the wet nitrocellulose. The gel in the casting tray is briefly rinsed in water 12 
to remove excess running buffer. It is then carefully moved from the tray onto the 13 
stack. We recommend adding extra buffer on the nitrocellulose to prevent 14 
bubbles from becoming trapped under the gel. The remaining three pre-wetted 15 
GB002 pieces are placed on top of the gel. To ensure thorough contact between 16 
all layers, a pipette should be rolled firmly across the top of the stack. The 17 
transfer stack is subsequently flanked with two elevated trays containing 1 x TBS 18 
and the pre-wetted wick is draped across the stack such that either end of the 19 
wick is submerged in 1 x TBS. Finally, the assembled transfer stack is covered 20 
with an additional plastic tray bearing extra weight (e.g. a small bottle of water) to 21 
ensure proper contact between all layers of the stack. The transfer should 22 
proceed for a minimum of three hours, although we generally transfer over night. 23 
 17 
After the transfer, the membrane can be processed by standard 1 
immunodetection procedures. 2 
 3 
2.1.4. Filter retardation assay using yeast protein lysates 4 
Another convenient method for analyzing aggregation is the size-dependent 5 
retention of aggregates on non-binding membranes (Figure 1D). This assay was 6 
initially developed to investigate amyloid formation of huntingtin in in vitro 7 
aggregation assays (Scherzinger et al. 1997), but it can also be used to detect 8 
aggregates in yeast cell lysates. Cells should be processed as for SDD-AGE 9 
(section 2.1.3), except that the sample buffer is omitted. Instead, the lysates are 10 
treated with the desired detergent- or chaotrope-containing buffer. Generally, we 11 
use SDS at 0.1-2%. Samples are incubated at room temperature for 10 min, or, 12 
for a negative control, boiled in 2% SDS. 13 
 During this incubation period the vacuum manifold is prepared. First, a thin 14 
filter paper (GB002) that is soaked in water is placed on the manifold. Then, a 15 
cellulose acetate membrane (pore size 0.2 µm) is soaked in PBS containing 16 
0.1% SDS and placed on top of the filter paper on the manifold. The manifold is 17 
closed and the samples are loaded into the wells of the manifold. The samples 18 
are filtered through the membrane by applying a vacuum and the membrane is 19 
washed 5 times with PBS containing 0.1% SDS. The cellulose acetate 20 
membrane can then be used for immunodetection with a protein-specific 21 
antibody. To demonstrate that equal amounts of protein were present in the 22 
samples, the same procedure can be repeated with a protein-binding 23 
 18 
nitrocellulose membrane. As with SDD-AGE, it is important for filter retardation 1 
experiments to include protein aggregation standards, such as [psi-] and [PSI+] 2 
cell lysates or lysates of yeast cells overexpressing the huntingtin length variants 3 
Q25 and Q103. 4 
 5 
2.2. Assays for prion behavior 6 
Prions are amyloids that are transmissible. Fragments of amyloid fibrils can be 7 
passed between cells or organisms, and the self-templating ability of amyloid 8 
results in the amplification of the structure, giving prions an infectious property. 9 
The prion properties of yeast prions reside in structurally independent prion- 10 
forming domains (PrDs). The PrDs of Sup35p and other prions are modular and 11 
can be fused to non-prion proteins, thereby creating new protein-based elements 12 
of inheritance (Li and Lindquist 2000). We employ two assays which exploit this 13 
property of prions to experimentally determine whether a predicted PrD can 14 
confer a heritable switch in the function of a protein. The assays are based on 15 
the well-characterized prion phenotypes of the translation termination factor 16 
Sup35p and the nitrogen catabolite regulator Ure2p. 17 
 18 
2.2.2. Sup35p-based prion assay  19 
Sup35p consists of an N-terminal PrD (N), a highly charged middle domain (M) 20 
and a C-terminal domain (C), which functions in translation termination. Both the 21 
N and M domains are dispensable for the essential function of Sup35p in 22 
translation termination. The charged M domain serves to increase the solubility of 23 
 19 
the amyloid-forming N domain, thereby promoting the conformational bistability of 1 
the Sup35p protein. In the prion state, a large fraction of the cellular Sup35p is 2 
sequestered into insoluble aggregates, resulting in reduced translation 3 
termination activity and an increase in the read-through of stop codons. 4 
Premature stop codons in genes of the adenine synthesis pathway, which are 5 
present in lab strains such as 74D-694, provide a convenient way to monitor 6 
switching of Sup35p to the prion state (Figure 2A). In prion-free [psi-] cells, 7 
translation termination fidelity is high, leading to the production of truncated and 8 
non-functional Ade1p. As a consequence the [psi-] cells are unable to grow on 9 
adenine-free medium and accumulate a byproduct of the adenine synthesis 10 
pathway that confers a red colony color when grown on other media such as 11 
YPD. Prion-containing [PSI+] cells, on the other hand, have a reduced translation 12 
termination activity that allows read-through of the ade1 nonsense allele and the 13 
production of functional full-length Ade1p protein, resulting in growth on adenine- 14 
deficient medium and the expression of a white colony color.  15 
 The modular nature of prion domains enables the generation of chimeras 16 
between the C or MC domain of Sup35p and candidate PrDs that can then be 17 
tested for their ability to generate [PSI+]-like states (Figure 2A). For several years 18 
plasmids have been available that allow the cloning of a candidate PrD N 19 
terminal to the C or MC domain of Sup35p (Sondheimer and Lindquist 2000; 20 
Osherovich and Weissman 2001). These plasmids can be integrated into the 21 
yeast genome to replace the endogenous SUP35 gene. This procedure, 22 
however, is very laborious and has a low success rate, as the resulting strains 23 
 20 
frequently express the chimera at levels much lower than wild type Sup35p. As a 1 
consequence, these strains aberrantly display a white colony color and show 2 
constitutive growth on medium lacking adenine, preventing their use in prion 3 
selection assays.  4 
 To overcome these difficulties, we recently developed a yeast strain 5 
(YRS100) in which a deletion of the chromosomal SUP35 is covered by a 6 
Sup35p-expressing plasmid (Alberti et al. 2009). When these cells are 7 
transformed with expression plasmids for PrD-SUP35C chimeras, a URA3 8 
marker on the covering SUP35 plasmid allows it to be selected against in 5-FOA- 9 
containing medium (plasmid shuffle). The resulting strains contain PrD-Sup35C 10 
fusions as their only source of functional Sup35p. This plasmid-based expression 11 
system is more versatile than the previous versions, as it easily allows the use of 12 
different promoters and therefore a better control over the expression level of 13 
PrD-Sup35 proteins. We have generated vectors with four different promoters, 14 
which have the following relative strength of expression: SUP35 < TEF2 < ADH1 15 
< GPD. To minimize the time needed for strain generation, these vectors enable 16 
recombination-based cloning using the Gateway® system. In recent years, the 17 
Gateway® system has emerged as a very powerful cloning method that allows 18 
for the rapid in vitro recombination of candidate genes into diverse sets of 19 
expression vectors. We have generated hundreds of Gateway®-compatible yeast 20 
expression vectors, each with a different promoter, selectable marker or tag 21 
(Alberti et al. 2007; Alberti et al. 2009). This technological improvement now 22 
allows us to perform high-throughput testing of candidate PrD libraries for prion 23 
 21 
properties. All Gateway-compatible plasmids described here are available 1 
through the non-profit plasmid repository Addgene (www.addgene.org). 2 
 The SUP35C and related fusion assays were instrumental in identifying 3 
new prions and prion candidates (Sondheimer and Lindquist 2000; Osherovich 4 
and Weissman 2001; Alberti et al. 2009; Nemecek et al. 2009). However, it can 5 
be difficult to work with PrD-Sup35 chimeras and it is therefore important to know 6 
about the shortcomings of this assay. Whether a Sup35p-based prion selection 7 
experiment will be feasible or not critically depends on the expression level of the 8 
PrD-Sup35C fusion protein and its functional activity in translation termination. 9 
Too low or too high levels of active Sup35p result in permanently elevated levels 10 
of stop codon read-through, with corresponding [prion-] strains that are able to 11 
grow on adenine-deficient medium and a colony color that is shifted to white 12 
(Figure 2B). It is therefore important to find the right window of expression to 13 
generate strains with adequate translation termination fidelity. In our lab we 14 
obtained the best expression results with the ADH1 promoter. 15 
 In general, a sufficient level of translation termination activity is indicated 16 
by a light to dark red colony color. Strains with pink or white colony colors usually 17 
have too high levels of translation termination activity and can thus not be used in 18 
prion selection assays that test for the ability to grow on adenine-deficient 19 
synthetic media (Figure 2B). In rarer cases it is possible that a high level of read- 20 
through is not caused by insufficient expression levels, but by constitutive 21 
aggregation of the PrD. To rule out that the PrD-Sup35C chimera is already 22 
present in an aggregated state, an SDD-AGE followed by immunoblotting with an 23 
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anti-Sup35p antibody should be performed. It is also important to point out that 1 
the size of the PrD that is fused to Sup35p is a key factor that determines 2 
functionality of the chimera. Based on our experience, PrDs between 60 and 250 3 
amino acids are well tolerated. PrDs above this threshold, however, tend to 4 
inhibit the translation termination activity of Sup35p. In some cases it can be 5 
important to include a solubilizing domain such as the M domain between the 6 
PrD and the C domain, as it could slow down the aggregation kinetics, a property 7 
that is particularly desirable if a protein is very aggregation-prone. 8 
 To generate a PrD-Sup35C-expressing strain, we introduce the 9 
corresponding expression plasmid into the YRS100 strain and select the 10 
transformants on appropriate selective plates. The transformants are isolated, 11 
grown in liquid medium for a few hours and then plated on 5-FOA plates to 12 
counterselect the covering SUP35 plasmid. Colonies growing on 5-FOA plates 13 
are streaked on YPglycerol to select for cells with functional mitochondria and 14 
eliminate petite mutants that change the colony color to white. Subsequently, the 15 
cells are transferred onto YPD plates to assess the colony color phenotype. In 16 
rare cases strain isolates expressing the same construct can vary in colony color. 17 
We therefore recommend isolating a number of different colonies and using the 18 
isolates with the predominant colony colors for subsequent experiments.  19 
 At this stage, some strains might already show switching between a red 20 
and a white colony color on YPD plates, indicating that the PrD under 21 
investigation has prion properties. The strains can then be plated on SD medium 22 
lacking adenine to more thoroughly select for the prion state. However, switching 23 
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rates of prions can be as low as 10-6 to 10-7. Therefore, in cases where 1 
spontaneous switching is not observed, conformational conversion to the prion 2 
state should be induced. Amyloid nucleates in a concentration-dependent 3 
manner. Thus transient overexpression of the PrD can be used to increase the 4 
switching frequency of a prion. To do this, we usually introduce an additional 5 
plasmid for expression of a PrD-EYFP fusion under the control of a galactose- 6 
inducible promoter. Induction of the prion state is achieved by growing the 7 
resulting transformants in galactose-containing medium for 24 hours. The cells 8 
are then plated on YPD and SD-ade plates at a density of 200 and 50,000 per 9 
plate, respectively. The same strains grown in raffinose serve as a control. A 10 
greater number of Ade+ colonies under inducing conditions suggests that 11 
expression of cPrD-EYFP induced a prion switch. In these cases the Ade+ 12 
colonies should be streaked on YPD plates to determine if a colony color change 13 
from red to white or pink has occurred. Often several colony color variants can be 14 
observed in one particular PrD-SUP35C strain. This could be due to the 15 
presence of weak and strong prion variants, or “strains”, that have been reported 16 
previously for other prions (Tessier and Lindquist 2009). A single prion protein 17 
can generate multiple variants that differ in the strength of their prion phenotypes. 18 
The underlying basis for this phenomenon is the presence of initial structural 19 
differences in the amyloid-forming nucleus that are amplified and maintained 20 
through the faithful self-templating mechanism of amyloids.  21 
 After having isolated several putative prion strains that exhibit a change in 22 
colony color, it is important to determine whether these changes are based on a 23 
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conformational conversion of the PrD-Sup35C protein. Known yeast prions 1 
critically depend on the chaperone disaggregase Hsp104p for propagation (Ross 2 
et al. 2005; Shorter and Lindquist 2005). Thus, deletion of the HSP104 gene or 3 
repeated streaking of the putative prion strains on YPD plates containing 5 mM of 4 
the Hsp104p inhibitor guanidinium hydrochloride (GdnHCl) are convenient ways 5 
of testing whether a color change is due to a prion switch. However, as some 6 
prion variants can propagate in the absence of Hsp104p, we suggest testing 7 
those that are resistant to Hsp104p inactivation for the presence of aggregated 8 
PrD-Sup35C by SDD-AGE and immunoblotting with a Sup35p-specific antibody. 9 
We found that many strains are able to switch to a prion-like state that is not 10 
based on a conformational change in the PrD-Sup35 protein, but involve other 11 
genetic or epigenetic changes of unknown origin. To rule out these false positive 12 
candidates, it is very important to rigorously test putative prion strains for the 13 
presence of conformationally altered PrDs.  14 
 15 
2.2.1. Ure2p-based prion assay 16 
Ure2p is a 354-amino acid protein consisting of an N-terminal PrD and a globular 17 
C-terminal region. The C-terminal region of Ure2p shows structural similarity to 18 
glutathione transferases and is necessary and sufficient for its regulatory 19 
function. Ure2p regulates nitrogen catabolism through its interaction with the 20 
transcriptional activator Gln3p. [URE3], the prion state of Ure2p, results in the 21 
constitutive activation of Gln3p, and the prion-containing cells acquire the ability 22 
to utilize poor nitrogen sources in the presence of a rich nitrogen source. One of 23 
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the genes activated by Gln3p is the DAL5 gene. It codes for a permease that is 1 
able to transport ureidosuccinate (USA), an essential intermediate of uracil 2 
biosynthesis. This ability to take up USA has historically been used to monitor the 3 
presence of [URE3] (Wickner 1994).  4 
 The N-terminal region of Ure2p is required for its prion properties in vivo 5 
and deletion of the N-terminal region has no detectable effect on the stability or 6 
folding of the C-terminal functional part of the protein. Analogous to the Sup35p 7 
assay described in the previous section, the Ure2p PrD can be replaced with a 8 
candidate PrD and the resulting chimera can then be tested for its ability to 9 
create heritable phenotypes that mimic [URE3] (Nemecek et al. 2009). Assaying 10 
[URE3] by selection on USA-containing plates has several disadvantages and for 11 
this reason we use a strain that contains an ADE2 reporter gene that is placed 12 
under the control of the DAL5 promoter (Brachmann et al. 2006). In prion-free 13 
[ure-o] cells, the ADE2 gene expression is repressed and no functional Ade2p 14 
protein is produced, resulting in a red colony color and an inability to grow on 15 
medium lacking adenine. Derepression of the DAL5 promoter in [URE3] cells, 16 
however, results in a switch to a white colony color and the ability to grow on 17 
adenine-free medium (Figure 3A).  18 
 We have also developed a yeast strain in which the chromosomal copy of 19 
the URE2 gene was deleted in the BY334 background (Brachmann et al. 2006). 20 
This strain was fully complemented by transformation of an expression plasmid 21 
for Ure2p (data not shown). In order to use this strain for the detection of novel 22 
prions, we generated Gateway® vectors for the formation of chimeras between a 23 
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candidate PrD and Ure2C (amino acids 66-354). The C terminus of Ure2p 1 
contains an HA tag that allows the detection of PrD-Ure2C chimeras with HA- 2 
specific antibodies. In addition, these vectors are available with three different 3 
promoters that can be used to express PrD-Ure2C chimeras at different levels 4 
(TEF2 < ADH1 < GPD). Using these vectors, we tested the PrDs of two well- 5 
characterized yeast prions, Sup35p and Rnq1p, for their ability to undergo prion 6 
switching when fused to the C-terminal domain of Ure2p. A chimera between the 7 
PrD domain of Sup35p and the C-terminal domain of Ure2p showed prion 8 
switching and formed weak and strong prion strains (Figure 3B and 3C). A fusion 9 
between the PrD of Rnq1p and Ure2C also behaved as a prion, with at least two 10 
different color variants (Figure 3D and 3E). Additionally, we found that even the 11 
full-length Rnq1p protein, when fused to Ure2C, resulted in a fully functional 12 
chimera that showed prion-dependent inactivation (data not shown). This finding 13 
suggests that the C domain of Ure2p is much more tolerant of larger PrDs than 14 
the C domain of Sup35p. We tested additional previously described PrDs for their 15 
ability to induce switching when fused to Ure2C and we found that many of these 16 
showed prion switching behavior (data not shown).  17 
 Despite its usefulness as a tool for the detection of prion switching 18 
behavior, there are disadvantages associated with the Ure2C-based selection 19 
system. The selection for the prion state of a PrD-Ure2C chimera on adenine- 20 
deficient media is usually very difficult due to high levels of background growth. 21 
Therefore, in those cases in which a prion state cannot be isolated by selection, 22 
we suggest identifying prion-containing strains based on colony color changes on 23 
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media containing adenine. We noticed that the PrD-Ure2C fusions readily enter 1 
an aggregated state, which is probably due to the fact that the C domain of 2 
Ure2p does not have a solubilizing effect as strong as the C domain of Sup35p. 3 
In many cases, the high switching rates of PrD-Ure2C fusions allowed us to 4 
readily isolate several prion-containing strains from a single plate. Again, it is 5 
important to establish that the putative prion phenotypes are based on a 6 
conformationally altered state of the PrD-Ure2C chimera. The methods that are 7 
most convenient for testing are repeated streaking on plates containing GdnHCl 8 
or SDD-AGE followed by immunoblotting with an HA-specific antibody. 9 
 10 
2.2.3. Prion selection assays 11 
All yeast prions described to date cause a loss-of-function when in the prion 12 
state, but it is also conceivable that prion switches induce a gain-of-function 13 
phenotype, as has been described for the CPEB protein that is involved in long- 14 
term memory formation (Si et al. 2003). To rigorously establish that a candidate 15 
protein operates as a prion in a physiologically relevant manner, robust prion 16 
selection assays have to be applied to isolate a prion-containing strain. The 17 
functional annotation of the yeast genome is a tremendously powerful resource 18 
for unraveling the biology of putative prions. A wealth of data from genome-wide 19 
deletion and overexpression screens as well as chemical and phenotypic 20 
profiling studies is now available to design functional prion assays (Zhu et al. 21 
2003; Cooper et al. 2006; Sopko et al. 2006; Hillenmeyer et al. 2008).  22 
 28 
The transcriptional activity of a putative prionogenic transcription factor, for 1 
example, can be monitored in a transcriptional reporter assay. We recently used 2 
such an approach to verify the prion properties of Mot3p (Alberti et al. 2009). 3 
Mot3p is a globally acting transcription factor that modulates a variety of 4 
processes, including mating, carbon metabolism, and stress response. It tightly 5 
represses anaerobic genes, including ANB1 and DAN1, during aerobic growth. 6 
To analyze Mot3p transcriptional activity, we created Mot3p-controlled 7 
auxotrophies by replacing the ANB1 or DAN1 ORFs with URA3. The resulting 8 
strains could not grow without supplemental uracil due to the Mot3p-mediated 9 
repression of URA3 expression. However, URA3 expression and uracil-free 10 
growth could be restored upon reduction of Mot3p activity, as with MOT3 deletion 11 
or inactivation of Mot3p by prion formation.  12 
 To select for the Mot3p prion state, we transiently overexpressed the 13 
Mot3p PrD, via a galactose-inducible expression plasmid, and plated the cells 14 
onto media lacking uracil. We isolated Ura+ strains whose phenotype persisted 15 
even after the inducing plasmid had been lost. These putative prion strains were 16 
then analyzed using a variety of prion tests, including curing by inactivation of 17 
Hsp104, testing for non-Mendelian inheritance in mating and sporulation 18 
experiments and probing for an aggregated form of Mot3p in prion-containing 19 
cells. Candidate-tailored prion selection assays analogous to the one developed 20 
for Mot3p allow the study of prion in their natural context, thus providing valuable 21 
insights into the biological functions of prion conformational switches.  22 
 23 
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2.2.4. Methods to analyze prion inheritance 1 
Yeast prions are protein-based epigenetic elements that are inherited in a non- 2 
Mendelian manner. The unusual genetic properties of yeast prions can be used 3 
to determine if a phenotype is based on a prion (Ross et al. 2005; Shorter and 4 
Lindquist 2005). Diploid cells that result from a mating between [prion-] and 5 
[PRION+] cells are usually uniformly [PRION+]. The genetic dominance emerges 6 
from the self-perpetuating nature of prions: when a prion-containing cell fuses 7 
with a prion-free cell, the efficient prion replication mechanism rapidly consumes 8 
non-prion conformers until a new equilibrium is reached that is shifted in favor of 9 
the prion conformer. Diploid [PRION+] cells that undergo meiosis and sporulation 10 
normally generate [PRION+] progeny with a 4:0 inheritance pattern. However, 11 
stochastic deviations from the 4:0 pattern are possible, if the number of prion- 12 
replicating units or propagons is low, causing some progeny to receive no 13 
propagons and to correspondingly lose the prion state. 14 
 To establish whether a putative prion trait is inherited in a "protein only" 15 
cytoplasm-based manner through the cytoplasm, cytoduction can be performed. 16 
Cytoduction is an abortive mating in which the cytoplasms of a prion-free 17 
recipient cells and a prion-containing donor cell mix without fusion of the nuclei. 18 
Daughter cells with mixed cytoplasm but only one nucleus bud off from the 19 
zygote and can be selected (Conde and Fink 1976). As a result, donor cells only 20 
contribute cytoplasm, whereas recipient cells contribute cytoplasm and nucleus 21 
to the progeny. The recipient cells we use are karyogamy-deficient and carry a 22 
mitochondrial petite mutation termed rho0. As a consequence, recipient cells can 23 
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not fuse their nuclei with those of the donor cell and are unable to grow on a non- 1 
fermentable carbon source, such as glycerol, unless they receive wild-type 2 
mitochondria from the donor cytoplasm. Following cytoduction, haploid progeny 3 
are selected that retained the nuclear markers of the recipient strain but can also 4 
grow in medium containing glycerol. If the aggregated state of the candidate PrD 5 
was successfully transmitted through the cytoplasm, the selected cytoductants 6 
should display the prion phenotype under investigation. For a more detailed 7 
description of cytoduction we direct the reader to two recent articles on this topic 8 
(Liebman et al. 2006; Wickner et al. 2006). 9 
 10 
2.2.5. Transformation of prion particles 11 
The principal tenet of the prion hypothesis is that prions replicate in a protein-only 12 
manner, without the direction of an underlying nucleic acid template. The most 13 
rigorous proof for a prion, then, is to show that nucleic acid-free preparations of 14 
aggregated protein are “infectious” in and of themselves. That is, they have the 15 
capacity to convert cells to a stable prion state when they are introduced into 16 
those cells. Protein transformations have irrefutably established the protein-only 17 
nature of prion propagation for a number of yeast prions, and have also been 18 
used to show that the prion strain phenomenon results from conformational 19 
variations in the underlying amyloid structure. 20 
Protein transformations are generally done by fusing prion particles with 21 
recipient cell spheroplasts using polyethylene-glycol (see Figure 4). A selectable 22 
plasmid is typically cotransformed with the prion particles to allow for the 23 
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determination of total transformation efficiency, as prion protein preparations 1 
have variable infectivities. The transformed spheroplasts are allowed to recover 2 
in soft agar and then analyzed for the prion phenotype. The putative prion 3 
particles to be used for protein transformations can be obtained either from 4 
[PRION+] cells or from recombinant protein that has been allowed to aggregate 5 
in vitro. 6 
When using crude extracts, care must be taken to eliminate all viable non- 7 
lysed cells remaining in the extract (e.g. by centrifugation or filtration), as they 8 
may appear as false positive transformants otherwise. For this reason, we 9 
recommend performing control transformations without recipient cells to verify 10 
that there are no contaminating cells in the extract. Extracts from [PRION+] yeast 11 
can be generated either by spheroplasting (e.g. Section 2.1.3) or by glass bead 12 
lysis (Brachmann et al. 2005; King et al. 2006). Cleared lysates resulting from 13 
either of these procedures may be adequate for transformations without further 14 
manipulations in some cases. However, there are also a number of techniques 15 
that can be used to enrich prion particles relative to other cellular components 16 
and thereby improve transformation efficiencies. We direct the reader to the 17 
corresponding references concerning these procedures, which include: partial 18 
purification of aggregated protein by sedimentation (Tanaka and Weissman 19 
2006), sedimentation followed by affinity purification of the prion protein (King et 20 
al. 2006), and amplification of prion particles in cell extracts by seeding the 21 
conversion of exogenously added recombinant prion protein (Brachmann et al. 22 
2005; King et al. 2006). 23 
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The most rigorous proof that a protein is a prion is to transform cells to the 1 
[PRION+] state using purely recombinant protein that has been converted to the 2 
putative prion form in vitro. This procedure avoids potential confounding factors 3 
that are present in yeast extracts, and also allows one to easily generate highly 4 
concentrated infectious preparations without the need for labor-intensive 5 
enrichment of prion particles from [PRION+] yeast cells. 6 
We routinely purify yeast PrDs from E. coli and convert them to amyloid 7 
fibers in a near-physiological buffer (Alberti et al. 2009). To form infectious 8 
amyloids in vitro, denatured proteins are diluted from a GdnHCl stock to a final 9 
concentration of 10 µM in 1 ml assembly buffer (5 mM K2HPO4, pH 6.6; 150 mM 10 
NaCl; 5 mM EDTA; 2 mM TCEP) and rotated end-over-end for at least 24 hrs at 11 
room temperature. The formation of amyloid is most easily monitored by 12 
thioflavin T fluorescence (450 nm absorption, 482 nm excitation), added at 20 13 
fold molar excess, to aliquots taken from the assembly reaction. Following 14 
amyloid conversion, the reaction is centrifuged at maximum speed (20,000 rcf) in 15 
a table top centrifuge for 30 min at room temperature, and the pellet of 16 
aggregated protein resuspended in 200 µl PBS. The protein is then sonicated 17 
with a tip sonicator at the lowest setting for 10 seconds. Sonication shears 18 
amyloid fibers into smaller pieces, thereby greatly enhancing their infectivity. 19 
Proper negative controls are essential for interpreting protein 20 
transformations. Prions arise spontaneously at a low frequency and this 21 
frequency increases after cells are exposed to stress (Tyedmers et al. 2008). 22 
Consequently, the efficiency of transformation to [PRION+] must be normalized 23 
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against mock transformations, such as freshly diluted (soluble) prion protein, 1 
amyloid fibers of other prions, or [prion-] cell extract.  2 
Recipient cells are prepared for protein transformations by a gentle 3 
enzymatic removal of the cell wall (spheroplasting), using a protocol adapted 4 
from Tanaka et al., 2006. Many prions have an increased rate of appearance in 5 
yeast cells harboring the [PIN+] prion. For this reason, we recommend using [pin- 6 
] yeast to reduce background from the spontaneous appearance of the prion 7 
state of interest. Yeast are grown to an OD of 0.5 in YPD, harvested by 8 
centrifugation, and washed twice in sterile distilled water. The cells are then 9 
washed with 1 ml SCE (1 M sorbitol, 10 mM EDTA, 10 mM DTT (added just 10 
before use), 100 mM sodium citrate pH 5.8) and then resuspended in 1 ml SCE. 11 
60 µL lyticase solution (4.2 mg/ml lyticase (Sigma); 50 mM sodium citrate, pH 12 
5.8) is added and the cells are incubated for 20 to 30 min at 30°C while shaking 13 
at 300 rpm. It is very important that this step not be allowed to proceed for too 14 
long, or cells will lose viability. We recommend standardizing this step using 15 
identical aliquots of lyticase solution prepared from a single lot, which are stored 16 
at -80°C. The progress of spheroplasting can be monitored during this incubation 17 
by placing 2 µl of cells in 20 µl of 1% SDS and observing them under a 18 
microscope. Spheroplasts should lyse and be invisible or appear as ghost cells. 19 
The spheroplasts are harvested at 500 rcf for 3 min at room temperature, 20 
followed by washing twice with 1 ml of STC buffer (1 M sorbitol; 10 mM CaCl2; 10 21 
mM Tris-HCl, pH 7.5). Finally, the spheroplasts are resuspended in 0.5 ml of 22 
STC buffer. Spheroplasts are sensitive to shear forces and consequently must be 23 
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handled gently during all manipulations. To resuspend spheroplasts, we use a 1 1 
ml pipette tip that has ~ 1 cm of the tip removed.  2 
We add 100 µl of spheroplasts to 4 µl of 10 mg/ml salmon sperm DNA, 25 3 
µl of 0.1 mg/ml selectable plasmid (e.g. pRS316 for a URA3-marked plasmid) 4 
and 33 µl of the protein solution to be transformed. The final protein 5 
concentration of amyloid fibers should be ~ 10 µM, or if using yeast extract, 200- 6 
400 µg/ml total protein. The samples are tapped gently to mix and incubated for 7 
30 minutes at room temperature. Next, proteins are fused to spheroplasts by 8 
adding 1.35 ml PEG-buffer (20 % (w/v) PEG 8000; 10 mM CaCl2; 10 mM Tris- 9 
HCl, pH 7.5) and incubating for 30 minutes at room temperature. Note that the 10 
optimal concentration and molecular weight of PEG used in this step may vary 11 
depending on the transformed protein (Patel and Liebman 2007). Spheroplasts 12 
are collected at 500 rcf for 3 min at room temperature, and resuspended in 0.5 ml 13 
of SOS buffer (1 M sorbitol; 7 mM CaCl2; 0.25 % yeast extract; 0.5 % bacto- 14 
peptone), followed by incubation for 1 hour at 30°C with 300 rpm shaking. 15 
Meanwhile, 8 ml aliquots of spheroplast recovery media are prepared in 15 ml 16 
tubes and maintained in a 48°C water bath. The spheroplast recovery media 17 
needs to be selective for the plasmid (e.g. SD-ura) and for the prion state if 18 
desired (see below), and is supplemented with 1 M sorbitol and 2.5% agar. Each 19 
transformation reaction is diluted into one aliquot of media, mixed by gentle 20 
inversion, and overlayed immediately onto the appropriate selective plates that 21 
have been prewarmed to 37°C. 22 
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Plates are incubated at 30°C under high humidity until colonies develop 1 
(up to one week). Colonies can then be picked out of the soft agar and scored for 2 
[PRION+] phenotypes. If transformation efficiencies are low, it is especially 3 
important that putative [PRION+] transformants are verified by secondary assays 4 
like SDD-AGE, to distinguish them from genetic revertants or other background 5 
colonies. 6 
We and others (Brachmann et al. 2005) have found that selecting directly 7 
for the [PRION+] state of some prions (e.g. [MOT3+] and [URE3]) during 8 
spheroplast recovery increases conversion to the [PRION+] state relative to 9 
delaying selection until after the cells have recovered. Newly induced prion states 10 
are often initially unstable and seem to be lost at a high frequency under non- 11 
selective conditions. Consequently, applying an immediate mild selective 12 
pressure during the spheroplast recovery step can improve the apparent 13 
transformation efficiency by preventing many prion-containing spheroplasts from 14 
losing the prion state during colony formation in the sorbitol-containing media. 15 
However, stringent selective conditions can also inhibit spheroplast recovery 16 
resulting in drastically reduced transformation efficiencies. For instance, [URE3] 17 
spheroplasts recover at a low frequency when plated directly to USA containing 18 
media (Brachmann et al. 2005), and we have observed that [PSI+] spheroplasts 19 
generally recover poorly in adenine-deficient media. For each prion and selection 20 
scheme, there is likely to be an optimum window of selection stringency that 21 
maximizes the number of [PRION+] transformants recovered. 22 
 23 
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3. Concluding remarks 1 
Aggregation has been suggested to be a generic property of proteins (Chiti and 2 
Dobson 2006), but most proteins aggregate only under conditions that fall 3 
outside of the normal physiological range. Studies of proteins that aggregate 4 
under non-physiological experimental conditions have provided important 5 
insights into general aspects of protein aggregation. Yet proteins that aggregate 6 
under physiological conditions are much more interesting from a biological point 7 
of view. Recent studies show that misfolding and aggregation propensities are 8 
likely to be a dominant force in the evolution of protein sequences (Chen and 9 
Dokholyan 2008; Drummond and Wilke 2008). This hypothesis is further 10 
underscored by the presence of complex quality control mechanisms that govern 11 
the abundance and structure of protein aggregates. Studies that identify large 12 
numbers of aggregation-prone proteins under physiological conditions will be 13 
necessary to understand how aggregation propensities shape the sequence and 14 
structure of proteins and the composition of proteomes. These studies will also 15 
allow us to generate comprehensive inventories of proteins that are capable of 16 
forming functional or pathological aggregates. Such inventories will be an 17 
important asset, as their analysis will facilitate the identification of sequence 18 
determinants that drive aggregation behavior. A growing toolbox of scalable and 19 
adaptable protein aggregation assays now enables us to rapidly identify and 20 
characterize the repertoire of aggregation-prone proteins in yeast. Once more, 21 
yeast is found at the vanguard of new technological developments that could turn 22 
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out to have a tremendous impact on our understanding of fundamental aspects 1 
of organismal biology.  2 
 3 
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Figure legends 
 
Figure 1: Diverse biochemical assays used to detect protein aggregation in 
yeast cell lysates. (A) Fluorescence microscopy was used to identify cellular 
aggregation patterns of proteins that are expressed as fusions to GFP. GFP 
alone (left) is equally distributed throughout the cytosol and nucleus. Two 
aggregation-prone proteins show annular or punctate fluorescent foci, 
respectively, resulting from the tight packing of amyloid fibrils in the cytosol. (B) 
Lysates of yeast cells expressing a GFP-tagged prion protein were analyzed by 
SDD-AGE and Western blotting. The prion protein was detected by 
immunoblotting with an anti-GFP antibody. (C) [prion-] and [PRION+] cell lysates 
were subjected to a filter retardation assay. Aggregates retained on the 
membrane were detected by immunoblotting. 
 
Figure 2: Using Sup35p to detect phenotype switching behavior. (A) Schematic 
representation of the Sup35p-based prion assay. The PrD of Sup35p is replaced 
with a candidate PrD and the resulting strains are tested for the presence of prion 
phenotypes, such as the switching between a red and a white colony color. (B) 
Relationship between the cellular concentration of Sup35p, the colony color and 
the ability to grow on synthetic medium lacking adenine. 
 
Figure 3: Using Ure2 to detect phenotype switching. (A) Schematic 
representation of a prion detection assay based on Ure2p. See text for further 
details. (B) A chimera between the PrD of Sup35p and the C-terminal region of 
Ure2p shows switching behavior in [RNQ+] cells. (C) SDD-AGE of different 
colony color isolates from a Sup35PrD-Ure2C strain. (D) A chimera between the  
Rnq1 PrD and Ure2C displays colony color switching in [RNQ+] cells. (E) SDD-
AGE of different colony color isolated from the plates in (D). 
 




